Research Article: I-PreFer Study: A Discrete Choice Experiment to Explore Patient, Caregiver and Pulmonologist Preferences of Idiopathic Pulmonary Fibrosis Pharmacological Treatment Options
Introduction:
Idiopathic pulmonary fibrosis (IPF) is the most common form of pulmonary fibrosis. It is a chronic, progressive, and ultimately fatal lung disease. Whilst considered rare, the incidence of IPF has risen over time. , There is currently no cure for IPF, except for lung transplantation in a small minority of patients. Without treatment, the median survival from diagnosis is three to five years. , There are two main antifibrotic pharmacotherapies currently available for IPF: pirfenidone and nintedanib. Both treatments…
Read more